Section Arrow
RNA.NASDAQ
- Avidity Biosciences
Quotes are at least 15-min delayed:2024/06/24 08:15 EDT
Last
 38.99
+1.38 (+3.67%)
Day High 
40.5 
Prev. Close
37.61 
1-M High
42 
Volume 
4.23M 
Bid
38.39
Ask
39.17
Day Low
38 
Open
38.33 
1-M Low
25.02 
Market Cap 
4.05B 
Currency USD 
P/E -- 
%Yield
10-SMA 34.22 
20-SMA 30.81 
50-SMA 27.8 
52-W High 42 
52-W Low 4.825 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.96/-2.18
Enterprise Value
4.06B
Balance Sheet
Book Value Per Share
7.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.56M
Operating Revenue Per Share
0.09
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MBIOMustang Bio0.5594-0.0011-0.20%-- 
DNAGinkgo Bioworks Holdings0.4244+0.0157+3.84%-- 
KTRAKintara Therapeutics0.2472-0.0277-10.08%-- 
BMRNBioMarin Pharmaceutical83.72-0.99-1.17%79.92PE
QLGNQualigen Therapeutics0.222+0.0449+25.35%-- 
Quotes are at least 15-min delayed:2024/06/24 08:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.